Neonatal Abstinence Syndrome | New England Journal of Medicine Skip to main content The
New England Journal of Medicine homepage Advanced Search SEARCH SPECIALTIES …

The incidence of neonatal opioid withdrawal syndrome (NOWS) has increased substantially
in the setting of the opioid epidemic, a major public health problem in the United States. At …

Importance Although opioids are used to treat neonatal abstinence syndrome (NAS), the
best pharmacologic treatment has not been established. Objective To compare the safety …

The incidence of perinatal opioid use and neonatal withdrawal continues to rise rapidly in
the face of the growing opioid addiction epidemic in the United States, with rural areas more …

Importance Observer-rated scales, such as the Finnegan Neonatal Abstinence Scoring Tool
(FNAST), are used to quantify the severity of neonatal abstinence syndrome (NAS) and …

Substance use among pregnant women is a major public health issue. Both prescription
opioid use and illicit opioid abuse have increased dramatically in recent years. Prolonged in …

The increasing use of opioids in pregnant women has led to an alarming rise in the number
of cases of neonates with drug-induced withdrawal symptoms known as neonatal opioid …

Background Neonatal abstinence syndrome (NAS) rates have dramatically increased.
Breastfeeding is a nonpharmacological intervention that may be beneficial, reducing NAS …

Infants exposed in utero to opioids will demonstrate a withdrawal syndrome known as
neonatal abstinence syndrome (NAS). Buprenorphine is a long‐acting opioid with …

Chronic intrauterine exposure to psychoactive drugs often results in neonatal opioid
withdrawal syndrome (NOWS). When nonpharmacologic measures are insufficient in …